Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced business updates and reported financial results for the first quarter ended March 31, 2024.
- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced business updates and reported financial results for the first quarter ended March 31, 2024.
- Verastem Oncology ended the first quarter of 2024 with cash, cash equivalents and investments of $110.1 million.
- Research & development expenses for the 2024 Quarter were $17.7 million, compared to $12.0 million for the 2023 Quarter.
- Selling, general & administrative expenses for the 2024 Quarter were $10.4 million, compared to $7.3 million for the 2023 Quarter.